特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

炭疽病治療の世界市場:2019年~2023年

Global Anthrax Treatment Market 2019-2023

発行 TechNavio (Infiniti Research Ltd.) 商品コード 754236
出版日 ページ情報 英文 103 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.59円で換算しております。
炭疽病治療の世界市場:2019年~2023年 Global Anthrax Treatment Market 2019-2023
出版日: 2018年11月20日 ページ情報: 英文 103 Pages
概要

世界中の炭疽菌ワクチンに関する研究資金の増加によって、市場成長を促進する可能性が高まっています。新たな資金提供により、追加のワクチン特性評価(解析)と粘膜免疫応答の検査が可能になります。 Technavioのアナリストは、世界の炭疽病治療市場が2023年までに8%以上のCAGRで成長すると予測しています。

当レポートでは、世界の炭疽病治療市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 調査範囲

第3章 市場状況

  • 市場のエコシステム
  • 市場特性
  • 市場セグメンテーション分析

第4章 パイプライン分析

  • パイプライン分析

第5章 市場規模

  • 市場の定義
  • 市場規模(2018年)
  • 市場規模および予測(2018年~2023年)

第6章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市場状況

第7章 市場セグメンテーション:製品別

  • 市場セグメンテーション:製品別(2018年~2023年)
  • 比較:製品別
  • ワクチン
  • 薬物療法
  • 市場機会:製品別

第8章 市場セグメンテーション:タイプ別

  • 市場セグメンテーション:タイプ別

第9章 顧客情勢

第10章 地域情勢

  • 地域別セグメンテーション(2018年~2023年)
  • 地域別比較
  • 南北アメリカ
  • 欧州・中東・アフリカ地域
  • アジア太平洋地域
  • 主要国
  • 市場機会

第11章 意思決定の枠組み

第12章 成長要因と課題

  • 市場の成長要因
  • 市場の課題

第13章 市場動向

  • 研究資金の増加
  • 新しい療法の開発の進展
  • バイオテロ関連炭疽菌ワクチンの開発

第14章 ベンダー情勢

  • 概要
  • 創造的破壊の状況

第15章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • Bayer
  • Elusys Therapeutics
  • Emergent BioSolutions

第16章 付録

  • 調査方法
  • 略語のリスト
図表
  • Exhibit 01: Global infectious disease treatment market
  • Exhibit 02: Segments of global infectious disease treatment market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Pipeline drugs in clinical trials
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Market condition - Five forces 2018
  • Exhibit 16: Product - Market share 2018-2023 (%)
  • Exhibit 17: Comparison by product
  • Exhibit 18: Vaccine - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 19: Vaccine - Year-over-year growth 2019-2023 (%)
  • Exhibit 20: Drug therapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Drug therapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Market opportunity by product
  • Exhibit 23: Customer landscape
  • Exhibit 24: Market share by geography 2018-2023 (%)
  • Exhibit 25: Geographic comparison
  • Exhibit 26: Americas - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 27: Americas - Year-over-year growth 2019-2023 (%)
  • Exhibit 28: EMEA - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: EMEA - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: APAC - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: APAC - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Key leading countries
  • Exhibit 33: Market opportunity
  • Exhibit 34: Impact of drivers and challenges
  • Exhibit 35: Vendor landscape
  • Exhibit 36: Landscape disruption
  • Exhibit 37: Vendors covered
  • Exhibit 38: Vendor classification
  • Exhibit 39: Market positioning of vendors
  • Exhibit 40: Bayer - Vendor overview
  • Exhibit 41: Bayer - Business segments
  • Exhibit 42: Bayer - Organizational developments
  • Exhibit 43: Bayer - Geographic focus
  • Exhibit 44: Bayer - Segment focus
  • Exhibit 45: Bayer - Key offerings
  • Exhibit 46: Elusys Therapeutics - Vendor overview
  • Exhibit 47: Elusys Therapeutics - Organizational developments
  • Exhibit 48: Elusys Therapeutics - Key offerings
  • Exhibit 49: Emergent BioSolutions - Vendor overview
  • Exhibit 50: Emergent BioSolutions - Business segments
  • Exhibit 51: Emergent BioSolutions - Organizational developments
  • Exhibit 52: Emergent BioSolutions - Key offerings
目次
Product Code: IRTNTR30185

About this market

The increase in funding for research on anthrax vaccine across the globe is likely to boost the market growth. The new funding will allow additional vaccine characterization and inspection of mucosal immune response. Technavio's analysts have predicted that the anthrax treatment market will register a CAGR of more than 8% by 2023.

Market Overview

Development of novel therapies for treatment of anthrax

There has been an increase in the development of novel therapies for anthrax due to the increasing threat of exposure to Bacillus anthracis among civilian populations and military forces.

Challenges associated with early diagnosis

There are challenges associated with early diagnosis of anthrax. Several anthrax cases have gone undetected. Such cases pose a threat to the anthrax treatment market.

For the detailed list of factors that will drive and challenge the growth of the anthrax treatment market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Bayer, and Emergent BioSolutions the competitive environment is quite intense. Factors such as the increase in development of new therapies and increase in research funding, will provide considerable growth opportunities to anthrax treatment manufactures. Bayer, Elusys Therapeutics, and Emergent BioSolutions are some of the major companies covered in this report.

'With the presence of a considerable number of companies, this market appears to be fragmented. This market research report will help clients identify new growth opportunities. Several companies are developing vaccines and therapeutics for bioterrorism-associated anthrax including Elusys Therapeutics.'

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: PIPELINE ANALYSIS

  • Pipeline analysis

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Vaccine - Market size and forecast 2018-2023
  • Drug therapy - Market size and forecast 2018-2023
  • Market opportunity by product

PART 08: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type

PART 09: CUSTOMER LANDSCAPE

PART 10: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 13: MARKET TRENDS

  • Increase in research funding
  • Increase in development of new therapies
  • Development of vaccines against bioterrorism-associated anthrax

PART 14: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 15: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bayer
  • Elusys Therapeutics
  • Emergent BioSolutions

PART 16: APPENDIX

  • Research methodology
  • List of abbreviations